Table 1. Baseline demographics.
IRF: intraretinal fluid, SD: standard deviation, SRF: subretinal fluid, VEGF: vascular endothelial growth factor
The data has been represented as number (n), percent (%), and mean +/- SD
| Anti-VEGF to faricimab n=19 eyes | |
| Age (years), mean (SD) | 78 (10) |
| Sex, n (%) | |
| Male | 11 (58.0%) |
| Female | 8 (42.1%) |
| Patients with fluid, n (%) | 19 (100%) |
| SRF | 7 (37.8%) |
| IRF | 9 (47.4%) |
| SRF + IRF | 3 (15.8%) |
| Duration of anti-VEGF treatment (days), mean (SD) | 1418 (1006.1) |
| Most recent treatment, n (%) | |
| Aflibercept | 16 (84.2%) |
| Ranibizumab | 1 (5.3%) |
| Brolucizumab | 1 (5.3%) |
| Bevacizumab | 1 (5.3%) |
| Baseline interval, weeks (SD) | 7.6 (2.8) |
| Interval between 3rd and 4th faricimab injection, weeks (SD) | 9.3 (3.9) |
| Fluid drying at 3rd injection, n (%) | |
| ≥99% | 7 (36.8%) |
| ≥50% to 98% | 7 (36.8%) |
| <50% | 5 (26.3%) |
| Letter increase at 3rd injection | |
| ≥5 | 7 (36.8%) |
| 1-5 | 4 (21.0%) |
| No improvement | 8 (42.1%) |